Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she has managed OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She attends conferences live and virtually to conduct video interviews and produce written coverage. Email: [email protected]
Alessandra Ferrajoli, MD, discusses the continued investigation of fixed-duration therapy as a frontline approach for patients with CLL, highlights both the pros and cons of this strategy, and touches on the unanswered questions regarding fixed-duration therapy that ongoing research aims to address.
Stephanie L. Graff, MD, expands on treatment options available for patients with premenopausal breast cancer who are trying to conceive, highlighting the POSITIVE trial in women with endocrine-responsive breast cancer.
Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.
Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.
Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.
Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.
The combination of the SHP2 inhibitor TNO155 and the KRAS G12C inhibitor JDQ433 showed antitumor activity in patients with KRAS G12C-mutated solid tumors, including non–small cell lung cancer, irrespective of prior treatment with a KRAS G12C inhibitor.
Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.
Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm.
Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.
Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.
Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.
Jue Wang, MD, highlights key takeaways regarding treatment sequencing for patients with relapsed/refractory urothelial carcinoma and the key factors that could help inform decisions for individual patients.
Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.
Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.
Hans Hammers, MD, PhD, outlines 3 cases of patients with renal cell carcinoma, detailing how each patient’s disease presented and how clinicians proceeded with treatment.
Breelyn Wilky, MD, discusses the rationale for investigating the addition of doxorubicin to zalifrelimab and balstilimab in patients with advanced/metastatic soft tissue sarcoma, expands on results from the phase 2 trial, and emphasizes the need for continued research for the potential role of immunotherapy in this patient population.
A neoadjuvant treatment regimen consisting of HER2-directed conventional dendritic cell intratumoral therapy plus paclitaxel, trastuzumab, and pertuzumab elicited pathologic complete responses in patients with stage I to III HER2-positive breast cancer.
Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.
Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.
Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.
Zeynep Eroglu, MD, explains the rationale for adding navitoclax to dabrafenib plus trametinib in the treatment of patients with BRAF V600–mutant metastatic melanoma, highlights the methodologies and results of the CTEP-P9466 trial, and describes the implications of this research for this patient population.
The novel personalized cancer vaccine IFx-Hu2.0 was found to be safe and well tolerated with weekly dosing in patients with checkpoint inhibitor–resistant cutaneous squamous cell carcinoma and Merkel cell carcinoma, according to data from an ongoing phase 1b trial.
Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.
Bhuvaneswari Ramaswamy, MD, and colleagues highlight treatment for patients with HR-positive breast cancer, discuss the role of pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, and expand on unmet needs for patients with metastatic HER2-positive breast cancer.
Pamela Kunz, MD, details key clinical trial updates across the gastrointestinal cancer arena presented during the 2023 ASCO Annual Meeting, including the phase 3 PROSPECT trial in locally advanced rectal cancer and the phase 3 IMbrave050 trial in patients with resected in hepatocellular carcinoma at high risk of recurrence.
Lionel Kankeu Fonkoua, MD, discusses the need for diverse representation across cancer clinical trials and research, emphasizes some of the disparities in enrollment criteria for these research efforts, and details some of the planned and ongoing initiatives at the Mayo Clinic that seek to facilitate change in the field.
Guru P. Sonpavde, MD, discusses key data presented from the phase 3 THOR and SWOG S1011 studies at the 2023 ASCO Annual Meeting, and details ongoing trials that could help advance precision medicine approaches for patients with bladder cancer.
Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.
